Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes

Rhea-AI Summary

Dexcom presented significant clinical data at the ADA 2024 conference, emphasizing the benefits of Dexcom CGM for people with Type 2 diabetes. The data highlights meaningful decreases in A1C and improved time in range for users of Dexcom CGM. Dexcom introduced new integrations with the Omnipod 5 Automated Insulin Delivery System and showcased updates to the Dexcom G7 app, including direct connectivity to Apple Watch. Dexcom G7's enhanced Bluetooth range and rapid reconnect features further enhance user experience. The studies also indicate that CGM is beneficial even for Type 2 diabetes patients not on insulin and those with prediabetes, demonstrating improved health behaviors and psychosocial health.

Positive

• Presentation of extensive clinical data showing Dexcom CGM's effectiveness in reducing A1C for Type 2 diabetes users.
• Introduction of Omnipod 5 with Dexcom G7, enhancing connectivity and user experience.
• Direct to Apple Watch update for Dexcom G7, allowing hands-free diabetes management.
• Enhanced Bluetooth range and rapid reconnect features improving Dexcom G7's usability.
• Studies indicate improved health behaviors and psychosocial health for prediabetes patients using Dexcom CGM.

Negative

• None.

Insights

Financial Analyst

Dexcom's new clinical data presentations at the ADA 2024 conference have a notable financial relevance for several reasons:

The expansion of Dexcom’s CGM (Continuous Glucose Monitoring) market among Type 2 diabetes patients can translate into a larger customer base, thereby potentially increasing revenue. Clinical data showing statistically significant improvements in A1C levels and time-in-range for CGM users may drive adoption, especially as more patients and healthcare providers seek out proven, effective management tools. Additionally, the integration of Dexcom G7 with the Omnipod 5 Automated Insulin Delivery System and other insulin pumps puts the firm at the leading edge of diabetes care technology, creating a competitive moat.

The announcement also underscores Dexcom’s relentless push towards innovation with Direct-to-Apple Watch connectivity. While this may not directly impact financials immediately, it enhances brand loyalty and user retention, important for long-term revenue growth.

Short-term, the news could result in positive stock movement as investors react to the positive clinical data and the expanded market potential. Long-term, sustained revenue growth is likely if Dexcom can maintain its innovative edge and expand its user base.

Medical Research Analyst

The clinical data presented by Dexcom at ADA 2024 provides significant insights for medical professionals and stakeholders in diabetes care:

First, the increased use of CGM among Type 2 diabetes patients, both those on insulin and those not, highlights the versatility and broad applicability of Dexcom's products. The data demonstrating improved A1C levels and time-in-range without the need for insulin may change the management paradigm for Type 2 diabetes, emphasizing CGM as an early intervention tool.

Second, the integration with incretin therapies, such as GLP-1s, points to a synergistic approach to diabetes management that could improve patient outcomes further. This suggests that CGM is not just for patients with complex insulin needs but could become a staple in comprehensive diabetes care, potentially expanding the market significantly.

The implications for patient care are substantial, as better glucose control translates to a reduced risk of complications and improved quality of life. This could also reduce healthcare costs in the long term, offering a compelling value proposition for payers.

Tech Expert

The technological advancements highlighted in Dexcom’s recent announcements are a clear indicator of the company's ongoing commitment to improving user experience and system connectivity:

Firstly, the integration of Dexcom G7 with the Omnipod 5 Automated Insulin Delivery System and other insulin pumps enhances the product's interoperability, making it a more attractive option for users who require comprehensive diabetes management solutions. This level of connectivity is significant as it provides users with a more seamless experience, reducing the burden of manual data management.

Secondly, the introduction of Direct-to-Apple Watch connectivity for the Dexcom G7 is a noteworthy innovation. This feature not only enhances convenience for users but also positions Dexcom as a market leader in wearable medical technology. The ability to monitor glucose levels in real-time without the need for a smartphone could potentially increase adoption rates among tech-savvy and younger patient demographics.

From a technology standpoint, these advancements underscore Dexcom's leadership in the CGM space, reinforcing its competitive advantage through enhanced user experience and system integration.

• Dexcom unveils more clinical data reaffirming the benefits of Dexcom CGM use among people with Type 2 diabetes than at any previous ADA conference.
• ADA conference presentations reiterate the advantages of Dexcom CGM use alongside incretin therapies such as GLP-1s.^1,2
• New Dexcom G7 automated insulin delivery integrations^* further solidify the company’s undisputed leadership in CGM connectivity.
• Recently released Dexcom G7 app updates, including Direct to Apple Watch,^† demonstrate relentless commitment to innovation and improving user experience.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to innovation at the 84^th Scientific Sessions of the American Diabetes Association conference held June 21–24, 2024, in Orlando.

Dexcom: The CGM brand for people with Type 2 diabetes, prediabetes and those using GLP-1s

This year at ADA, Dexcom is presenting more data on Dexcom CGM use among people with Type 2 diabetes than ever before. This data shows clinically meaningful decreases in A1C and increases in time in range for Dexcom CGM users with Type 2 diabetes both on insulin and not on insulin.^3-5

Additionally, studies presented at the conference demonstrate Dexcom CGM use by people with Type 2 diabetes not on insulin is associated with improved A1C independent of anti-diabetes medication, and there may be further benefits of CGM for this population when used in combination with therapies such as GLP-1s.¹ As the use of GLP-1s continues to grow, data continues to show people with Type 2 diabetes on GLP-1s are more likely to use CGM after starting the medication.²

Going beyond Type 2 diabetes, another study presented at ADA demonstrates Dexcom CGM is a valuable behavior modification tool for people with prediabetes.⁶ In this study, Dexcom CGM use was associated with improved self-reported psychosocial health and self-care behaviors in participants with prediabetes including perceived benefits related to eating, physical activity, weight, blood pressure, worry, energy levels and healthcare provider interactions.

“As the evidence of the benefits of CGM use by people with Type 2 diabetes and prediabetes continues to grow, Dexcom is uniquely positioned to address their needs through our portfolio of products,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “Dexcom G7 is the most accurate and affordable⁷ CGM system available for people with Type 1 diabetes and Type 2 diabetes who use insulin, and when Stelo by Dexcom launches in late August, we will have a glucose biosensor available for purchase without a prescription designed specifically for people with Type 2 diabetes not using insulin.”

Dexcom: The clear choice for automated insulin delivery

Dexcom further solidified its position as the industry leader in connectivity this morning with Insulet’s announcement commencing the launch of the Omnipod 5 with Dexcom G7. Beginning today, new Omnipod 5 users can experience the benefits of the only tubeless AID system connected to Dexcom G7, the most accurate CGM⁷ powering AID systems. Dexcom G7 will be available for existing Omnipod 5 users in the U.S. later this year.

Dexcom CGM currently connects to more AID pump options than any other CGM brand in the U.S.; the iLet Bionic Pancreas insulin pump, the Tandem pump portfolio (Tandem Mobi and t:slim X2 insulin pumps), and now Omnipod 5. For those seeking more information about the recent integration of Dexcom G7 and the Tandem Mobi insulin pump, there will be an evening education event during ADA on June 22, 2024, from 6-8 p.m. Registration is open to U.S. healthcare provider attendees.

With hundreds of thousands of users now connected to insulin pumps, pens and digital health apps, Dexcom is the undisputed leader in CGM connectivity.

Dexcom: A relentless commitment to innovation and customer experience

For 25 years, Dexcom has been the pioneer in continuous glucose monitoring, continually innovating on behalf of people with diabetes. The release of new app updates this month has further improved the features and user experience of Dexcom G7, the world’s most accurate CGM system.⁷

Dexcom G7 is now the first and only CGM with Direct to Apple Watch connectivity, allowing users to leave their iPhone ^‡ behind and manage diabetes hands-free.​ It’s now the first and only CGM with automated activity and medication logging, helping users visualize how activity and medications affect glucose in real-time. And with enhanced Bluetooth with Rapid Reconnect, Dexcom G7 now has 65% farther ^§,8 Bluetooth range and quicker reconnection when signal is lost, keeping users connected longer.​

For a detailed overview of all the Dexcom CGM symposia and presentations at ADA this year, visit the Dexcom Clinical Education Resources Microsite.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers and providers, Dexcom works to simplify and improve diabetes management around the world. For more information on Dexcom, visit https://www.dexcom.com/about.

Category: IR

* To learn more about insulin pump integrations and compatibility with Dexcom CGM Systems, visit dexcom.com/integrate. ^† Smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility. ^‡ Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 20 feet of the Dexcom G7. ^§ Dexcom G7 now has a 33 ft Bluetooth range, 13 feet farther than the previous 20 ft range.

1 Nemlekar P, Hannah K, Norman GJ. The Combined Effect of CGM with Antidiabetes Medications and the Association with Improved A1C in People with Type 2 Diabetes (PWT2D) Not on Insulin Therapy (NIT). Poster presentation 1914-LB. 2 Wang A, Xu Y, Norman GJ, Reid JL, Singh H, Yang L. CGM Use in People with Type 2 Diabetes Initiating GLP-1 or GIP/GLP-1 RA Therapy – Real-World Data. Poster presentation 1922-LB. 3 Grace T, Layne JE, Hicks C, Green CR, Walker TC. The Dexcom Community Glucose Monitoring Project for People with Type 2 Diabetes – One Year Outcomes. Poster presentation 982-P. 4 Layne JE, Jepson LH, Carite A. Bergenstal RM, Long-term Improvement in CGM-Measured Glycemic Control in Adults with Type 2 Diabetes Not Treated with Insulin. Poster presentation 983-P. 5 Norman GJ, Fernandes J, Nemlekar P, Lupton L, Berk A. A1c Change After Initiating Continuous Glucose Monitoring (CGM) For People with Diabetes in a Large US Managed Health Care Plan. Oral presentation 143-OR. 6 Crawford MA, Hicks C, Zhou T, Xu Y, Singh H, Chernavvasky DR, Levister C, Shah N, Rouviere M, Tamru A, Kaplan L, Lam DW, O’Malley G, Levy, CL. Value of Dexcom CGM for Therapy Optimization and Glycemic Outcomes in Post-Hospital Discharge T2D Patients: An Exploratory Study. Poster presentation 1133-P. 7 Dexcom, data on file, 2024. 8 Dexcom G7 CGM System User Guide. 2023.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620606764/en/

Media Contact

James McIntosh

619-884-2118

james.mcintosh@dexcom.com



Investor Contact

Sean Christensen

858-203-6657

sean.christensen@dexcom.com

Source: DexCom, Inc.

FAQ

What clinical data did Dexcom present at ADA 2024?

Dexcom presented data showing Dexcom CGM's effectiveness in reducing A1C and improving time in range for Type 2 diabetes users.

When was the Dexcom and Omnipod 5 integration announced?

The Dexcom and Omnipod 5 integration was announced on June 21, 2024, during the ADA conference.

What new features does the Dexcom G7 app offer?

The Dexcom G7 app now offers direct connectivity to Apple Watch, enhanced Bluetooth range, and rapid reconnect features.

How does Dexcom CGM benefit Type 2 diabetes patients not on insulin?

Studies show Dexcom CGM benefits Type 2 diabetes patients not on insulin by reducing A1C and improving glycemic control.

What impact does Dexcom CGM have on people with prediabetes?

Dexcom CGM use is associated with improved self-reported health behaviors and psychosocial health in people with prediabetes.